Vlado Perkovic's Publications

• Kidney Disease as a Cardiovascular Disease Priority

  Journal articles

  2024

  Circulation

• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD A Meta-Analysis of CKD Progression Trials

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.

  Journal articles

  2024

  Eur Heart J

• Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

  Journal articles

  2024

  Circulation

• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

  Journal articles

  2024

  Circulation

• Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

  Journal articles

  2024

  New England Journal of Medicine

• Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.

  Journal articles

  2024

  Nephrol Dial Transplant

• Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

  Journal articles

  2024

  Circulation

• 456 Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study

  Journal articles

  2024

  Nephrology Dialysis Transplantation

• Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)

  Journal articles

  2024

  American Journal of Respiratory and Critical Care Medicine

• Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Daprodustat and Heart Failure in CKD

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

  Journal articles

  2024

  Kidney International Reports

• Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

  Journal articles

  2024

  Diabetes Care

• VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Barriers to Care: New Medications and CKD

  Journal articles

  2024

  Kidney International Reports

• Targeting APRIL in the Treatment of IgA Nephropathy

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  American Journal of Kidney Diseases

• Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin A Secondary Analysis of Randomized Clinical Trials

  Journal articles

  2024

  JAMA Cardiology

• Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Heart Association

• Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

  Journal articles

  2024

  Circulation

• Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

  Journal articles

  2024

  The Lancet Regional Health - Western Pacific

• The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

  Journal articles

  2024

  Kidney International Reports

• Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism